BREELIB
Research type
Research Study
Full title
Evaluation of patient experiences of Inhaled Iloprost using the Breelib nebulizer
IRAS ID
237814
Contact name
Janelle Yorke
Contact email
Sponsor organisation
University of Manchester
Duration of Study in the UK
1 years, 4 months, 0 days
Research summary
Pulmonary arterial hypertension (PAH) is a life-threatening condition characterised by vascular remodelling and increased pulmonary vascular resistance, ultimately leading to right heart failure. Inhaled Iloprost has proven efficacy and safety in patients with PAH and optimal dosage requires the patient to self-administer multiple inhalations a day – usually between six to nine inhalations. Recently, a new inhaled delivery device, the Breelib nebulizer (Vectura Group plc, Chippenham, UK), was developed specifically for Iloprost inhalation. In the UK, it is planned that all suitable patients are transitioned from I-Neb to Breelib between November 2017 and August 2018.
The aim of this observational study is to explore the experience and expectations of PAH patients transitioning to the new Breelib nebulizer. Furthermore, we will look at other health related outcomes & adherence to treatment to see how these are affected by the introduction of the new product.
The hypothesis is that patients will find the newer device easier to use and due to reduced drug delivery time, will have enhanced adherence and compliance.REC name
North West - Greater Manchester South Research Ethics Committee
REC reference
18/NW/0017
Date of REC Opinion
25 Jan 2018
REC opinion
Favourable Opinion